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Silent Ischemia
Clinical Relevance
C. Richard Conti, MD, Anthony A. Bavry, MD, MPH, John W. Petersen, MD, MS
Gainesville, Florida
Myocardial ischemia can occur without overt symptoms. In fact, asymptomatic (or silent) ST-segment depression
during ambulatory electrocardiogram monitoring occurs more often than symptomatic ST-segment depression in
patients with coronary artery disease. Initial studies documented that silent ischemia provided independent pre-
diction of adverse outcomes in patients with known and unknown coronary artery disease. The ACIP (Asymptom-
atic Cardiac Ischemia Pilot Study) enrolled patients in the 1990s and found that revascularization was better
than medical therapy in reducing silent ischemic episodes and possibly cardiovascular (CV) events. However, the
more recent COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial found
similar CV event rates between patients treated with optimal medical therapy alone and those treated with opti-
mal medical therapy plus percutaneous revascularization. Therefore, in the current era, medical therapy appears
to be as effective as revascularization in suppressing symptomatic ischemia and preventing CV events. COURAGE was
not designed to evaluate changes in the frequency of silent ischemia. Therefore, silent ischemia may persist de-
spite current-era treatment and might still identify patients with increased risk of CV events. Also, silent isch-
emia is likely to occur frequently in heart transplant patients with denervated hearts and coronary allograft vas-
culopathy, and future study aimed at improving the management of silent ischemia in this population is
warranted. Additionally, future research is warranted to study the effect of newer medical therapies such as ra-
nolazine or selected use of revascularization (for example, guided by fractional flow reserve) in those patients
with persistent silent ischemia despite optimal current-era medical therapy. (J Am Coll Cardiol 2012;59:
435–41) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.050Preventing and reversing myocardial ischemia in an effort to
protect myocardial tissue is a primary goal of cardiologists.
Most often, myocardial ischemia is encountered in patients
with symptoms; however, ischemia that occurs without
associated symptoms also has important prognostic impli-
cations. Asymptomatic (silent) ischemia may be identified
during routine daily activities or during stress testing. In the
1970s, asymptomatic ST-segment depression during ambu-
latory electrocardiogram (AECG) monitoring was shown to
occur more often than symptomatic ST-segment depression
in patients with coronary artery disease (CAD) (1). Impor-
tant work in the 1980s and 1990s suggested that silent
ischemia was associated with adverse events (2). Further,
randomized trials at that time suggested that revasculariza-
tion of patients with silent ischemia might improve clinical
outcomes (3); however, more recent studies have suggested
similar clinical outcomes in patients with stable CAD
treated with either aggressive risk factor–directed medical
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larization (4). Thus, review of the clinical significance of
silent ischemia in the current era is warranted.
Definition, Diagnosis, and Mechanism
After coronary artery occlusion, left ventricular mechanical
abnormalities and electrocardiogram (ECG) abnormalities
precede the development of symptoms (Fig. 1) (5,6). There-
fore, it is not surprising that patients can have evidence of
myocardial ischemia without symptoms. Silent ischemia is
typically defined as objective evidence of myocardial isch-
emia in patients without symptoms related to that ischemia.
Silent ischemia may be detected in patients who have no
symptoms during an exercise or pharmaceutical stress test
but who do have transient ST-segment changes, perfusion
defects, or reversible regional wall motion abnormalities.
Additionally, silent ischemia may be detected with the use
of AECG devices such as the Holter monitor. These
AECG monitors can detect ischemia with as few as 2 leads
and are typically worn for 24 to 48 h with recordings
analyzed using various computer algorithms (7). ST-
segment changes during AECG monitoring can be nonspe-
cific, and false positives do occur; thus, strict criteria are
necessary to support a diagnosis of silent ischemia. For
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diagnosed when ST-segment de-
pression is at least 0.5 mV and the
changes last at least 60 s and re-
verse to normal (8). More recently,
an implanted ECG monitor has
been described. The AngelMed
Guardian ischemia detection sys-
tem (Angel Medical Systems,
Shrewsbury, New Jersey) places a
pacemaker lead at the right ven-
tricular apex and continuously
monitors intracardiac electrocar-
diogram signals (9). The system
alerts the patient of abnormal ST-
segment deviations, and early
studies have suggested an improvement in time to presentation
after an ischemic event. AECG monitoring and implantable
devices have allowed for evaluation of silent ischemia over
longer periods of time and during routine daily activities.
Changes in either myocardial oxygen demand or supply
have been proposed as the mechanism of silent ischemia.
Many studies have suggested a demand mechanism of
ischemia by demonstrating an increase in heart rate prior
to silent ischemic events (10). Additionally, blood pres-
sure has been shown to increase in the minutes preceding
silent ischemic episodes (11). Other studies have sug-
gested that demand alone does not explain the cause of
silent ischemia; for example, the heart rate at which
asymptomatic ST-segment depression occurs during
AECG monitoring is significantly lower than the heart
rate at the onset of ST-segment depression during
exercise testing in the same patient (12). The combina-
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Figure 1 Sequence of Events Following Occlusion of a Coronar
Following coronary artery occlusion diastolic, systolic, and electrocardiographic (ECtion of an increasing demand and an altered supply
secondary to abnormal microvascular and endothelial
response is a possible explanation for the mechanism of
silent ischemia.
Prevalence
Asymptomatic myocardial ischemia has been shown to
occur more often than symptomatic ischemia in patients
with stable CAD (1). With AECG monitoring, nearly
one-half of patients with stable CAD are shown to have
transient ST-segment depressions that likely represent
silent ischemic events (13). Similarly, nearly one-half of
patients admitted with unstable angina will have silent
ischemia detected during continuous ECG evaluation
(14). Silent ischemia has also been documented in pa-
tients who only have risk factors for CAD; for example,
15% of patients with mild-to-moderate hypertension
who had no signs or symptoms of CAD had ST-segment
depression during AECG monitoring or with exercise
stress (15). Also, 12% of noninsulin-dependent diabetics
with no symptoms suggestive of CAD had abnormal
exercise ECGs (16), although only one-half of these
patients were found to have perfusion defects during
thallium scintigraphy. In another study, 33% of diabetic
patients with at least 1 additional cardiovascular risk
factor had silent ischemia (17). Finally, even healthy
patients without risk factors for CAD have been shown
to have silent ischemia. Twenty-four percent of appar-
ently healthy individuals either had an abnormal stress
ECG or stress perfusion study (18).
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Patients with stable CAD. In patients with mild-to-
moderate CAD, silent ischemia provides similar prognostic
information for adverse outcomes as does symptomatic
ischemia. In patients with medically managed CAD, the
likelihood of death or myocardial infarction during 7 years
of follow-up was similar between patients with asymptom-
atic ST-segment depression with exercise and those patients
with symptomatic ST-segment depression with exercise
(Fig. 2). However, among patients with medically treated
extensive CAD, silent ischemia is associated with worse
prognosis than symptomatic ischemia (19).
More recent studies have suggested that ST-segment
depression during AECG monitoring may be better than
exercise tests in predicting outcomes. In 1 study, 86 patients
with stable CAD and abnormal exercise ECGs were fol-
lowed for an average of 12.5 months (20). During the
follow-up period, there were 21 major cardiovascular (CV)
events, and all but 1 of these events occurred in patients with
AECG evidence of ST-segment depression. The number of
ST-segment depression events during AECG monitoring
correlated with exercise ECG findings, such as the time to
onset of ST-segment depression during exercise, duration of
exercise, and depth in millimeters of ST-segment depres-
sion during exercise. However, after multivariate adjust-
ment, only ST-segment depression during AECG moni-
toring, and not ST-segment depression during exercise,
significantly predicted worse outcomes. Similar results were
provided by a different study of patients with CAD who
were asymptomatic on antiangina therapies (2). Silent
ischemia during AECG monitoring was a more powerful
predictor of mortality than exercise duration, age, previous
myocardial infarction (or resting Q waves), hypertension,
diabetes, or smoking history.
Figure 2 Prognosis of Patients With Exercise-Induced Ischemia
Probability of remaining free of myocardial infarction and sudden death in control s
patients with medically treated CAD and ST-segment depression during exercise with (Patients with unstable angina. Silent ischemia is also
known to occur in patients who present with unstable
coronary syndromes (14). The presence of silent ischemia in
these patients provides important prediction of short- and
long-term risk. In patients with unstable angina that is
medically managed in a coronary care unit, evidence of silent
ischemia during 48 h of continuous ECG recording was
predictive of poor outcomes at 1 month and 2 years (21).
Patients after percutaneous coronary intervention. Si-
lent ischemia has also been predictive of outcomes in
patients who have undergone percutaneous coronary
intervention (PCI) with stents. Six months after success-
ful PCI, 14% of patients had evidence of silent target
vessel ischemia during exercise stress perfusion imaging
(22). Patients with silent ischemia had a smaller burden
of ischemia (average summed difference score of 2.8) than
those with symptomatic ischemia (average summed dif-
ference score of 5.9). Accordingly, compared with pa-
tients with no ischemia, silent ischemia is associated with
increased adverse events but not to the extent of symp-
tomatic ischemia (Fig. 3). Whereas this study docu-
mented a persistent, although attenuated hazard from
silent ischemia after PCI, it is still unclear if detecting
asymptomatic ischemia can help to improve outcomes.
The ADORE (Aggressive Diagnosis Of REstenosis) trial
evaluated the benefit of screening for silent ischemia with
routine stress testing after PCI as compared to perform-
ing stress testing only in those with symptoms (23).
Patients with PCI were randomized to either scheduled
stress tests in which they had an exercise ECG at 6 weeks
and an exercise ECG with nuclear perfusion imaging at 6
months versus selective stress testing, in which stress
testing was only performed if patients developed a clinical
indication. There was no difference in functional status,
or Without Symptoms
ts who had no known history of coronary artery disease (CAD), and in
#2) or without (Group #1) angina. Reprinted, with permission, from Weiner et al. (19).With
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months after PCI between the 2 groups. These findings
support the American College of Cardiology/American
Heart Association guideline recommendations to not
routinely perform stress tests in asymptomatic patients
after revascularization without specific indications (24).
Healthy subjects. Silent ischemia detected in healthy
ndividuals with no known CAD has also been shown to
redict adverse events. Among 407 healthy individuals
ith ages ranging from 40 to 96 years, 9.8% had a
ignificant cardiac event during a mean follow-up of 4.6
ears (18). An abnormal exercise ECG and thallium
erfusion study provided independent prediction of ad-
erse events. The degree of silent ischemia may be more
mportant than the simple presence of silent ischemia in
he prediction of future events. Zellweger et al. (25)
valuated 3,664 consecutive asymptomatic patients with-
ut known CAD who had undergone myocardial perfu-
ion imaging. They determined that if a subject had
7.5% ischemic myocardium, then their risk of a CV
vent was significantly increased.
ost-transplant patients. Coronary allograft vasculopathy,
hich can result in myocardial ischemia, is a significant
roblem in patients who have had a heart transplantation
26). Because these patients have denervated hearts, they
arely present with symptoms. Instead they present with
eart failure after suffering multiple small myocardial in-
arcts. Although the management of coronary allograft
asculopathy is beyond the scope of this manuscript, the
iagnosis and treatment of these patients with silent isch-
mia is currently suboptimal, and further research is
Figure 3 Survival After PCI in Patients With Ischemia With or W
Probability of event-free survival by symptomatic and ischemic status. Reprinted, warranted.Medical Therapy and Revascularization
The ACIP trial. Because silent ischemia has shown to
predict poor outcomes, it is not surprising that many
investigators have attempted to determine if interventions
that reduce silent ischemia improve outcomes. The ACIP
(Asymptomatic Cardiac Ischemia Pilot Study) tested vari-
ous strategies to reduce silent ischemia. Eligible patients had
evidence of asymptomatic ischemia on AECG, an abnormal
exercise ECG, and stable CAD with at least a 50% stenosis
(13). Whereas most of the patients had angina symptoms at
study enrollment, approximately one-third were asymptom-
atic. Participants were randomized to medical therapy versus
revascularization. Medical therapy was further divided into
an angina-guided strategy with the use of antiangina med-
ications to eliminate symptoms and an ischemia-guided
strategy with the use of antiangina medications to eliminate
silent ischemia on AECG monitoring. Angina or ischemia
was controlled with either atenolol (with nifedipine XL if
necessary) or diltiazem SR (with isosorbide dinitrate if
necessary). Patients in the revascularization arm could
receive either balloon angioplasty or coronary artery bypass
graft (CABG) as appropriate. It is important to note that
this study predated the use of coronary stents. The primary
outcome at 12 weeks was the absence of ischemic episodes
on AECG. At 12 weeks, patients who were revascularized
had more significant suppression of ischemic events during
AECG monitoring than did patients in either of the
medical therapy groups (27). Specifically, 55% of patients in
the revascularization group had no ischemic episodes on
AECG, compared with 39% of patients in the angina-
guided group and 41% of patients in the ischemia-guided
ut Symptoms
rmission, from Zellweger et al. (22). PCI  percutaneous coronary intervention.itho
ith pegroup. There was no significant difference in the proportion
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between either of the 2 medical therapy groups. Impor-
tantly, the ACIP investigators demonstrated a trend toward
decreased CV event rates in those patients with a greater
reduction of ischemic episodes during follow-up AECG
(28). Therefore, it is not surprising that the secondary
composite outcome of death, myocardial infarction, revas-
cularization, or hospitalization for unstable angina at 1 year
was lowest in the revascularization group (Fig. 4) (29).
Decrease in CV event rates with revascularization was also
evident at 2 years (3). However, there was no difference in
event rates between either of the medical therapy groups. In
conclusion, ACIP demonstrated increased suppression of
ischemic episodes and decreased CV outcomes in patients
treated with revascularization as compared with medical
therapy.
The COURAGE trial. ACIP set the stage for the
COURAGE (Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation) trial. This large study
randomized 2,287 patients with stable angina to PCI plus
optimal medical therapy versus optimal medical therapy
alone (4). COURAGE did not specifically evaluate for
silent ischemia; however, if examined, this likely would have
been observed in a large proportion of participants (13).
Moreover, 13% of participants were asymptomatic at base-
line. Study protocol allowed liberal use of extended-release
metoprolol (89% vs. 85%), amlodipine (49% vs. 40%), and
isosorbide mononitrate (67% vs. 53%), for the medical
versus PCI groups (percentages listed, respectively). Aspi-
rin, statins, and angiotensin-converting enzyme (ACE)
inhibitors/angiotensin receptor blockers were also used in
Figure 4 1-Year Cumulative Rates of Death, MI, or Cardiac Hos
Event rates were significantly different between the revascularization group and bo
between either of the medical therapy groups. Reprinted, with permission, from Ro
artery bypass graft; MI  myocardial infarction; PTCA  percutaneous transluminathe majority of patients. This contrasts with medical therapy
in ACIP where the use of these background medications
was quite low; for example, in ACIP, only 42% of patients
in the medical therapy groups and 20% of patients in the
revascularization group were on a beta-blocker (atenolol) at
12 weeks (27). Additionally, statin medications were not
recorded in ACIP and were presumably used in only a small
minority of patients.
COURAGE documented similar outcomes, by intention
to treat, between the medical therapy and PCI groups. At a
median follow-up of 4.6 years, death or myocardial infarc-
tion had occurred in 18.5% of the medical therapy group
versus 19.0% of the PCI group (p  0.62). In the PCI
group, 21% required repeat revascularization, whereas 33%
of the medical therapy group crossed over to revasculariza-
tion (p 0.001). The findings of COURAGE do not apply
to angina patients with high-risk coronary anatomy. Re-
search published in the 1990s reported decreased adverse
clinical outcomes in patients with left main trunk or
multivessel CAD treated with CABG as compared to
medical therapy (30). However, the recently published
STICH (Surgical Treatment for Ischemic Heart Failure)
trial suggested no difference in all-cause mortality between
patients with CAD and left ventricular ejection fraction
35%, who received medical therapy plus CABG versus
medical therapy alone, although CV mortality was reduced
by CABG (31). At 1 year, the adherence to medical therapy
was high and not different between the 2 treatment groups
in STICH, with more than 80% of patients on aspirin,
statin, beta-blockers, and ACE inhibitors. These findings
along with those of COURAGE suggest that in certain
ization in ACIP
angina-guided and ischemia-guided groups. Event rates were not different
t al. (29). ACIP  Asymptomatic Cardiac Ischemia Pilot Study; CABG  coronary
ary angioplasty.pital
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impact on ischemia reduction to that of revascularization.
Optimal medical therapy beyond COURAGE. Because
of the evolving importance of optimal medical therapy, it
is important to discuss in more detail the various phar-
maceutical agents that can be used to control angina and
reduce frequency of silent ischemia. The CAPE (Circa-
dian Anti-Ischemia Program in Europe) II trial found
that amlodipine (10 mg daily) plus atenolol (100 mg
daily) was associated with less ambulatory ischemia than
extended release diltiazem (300 mg daily) plus isosorbide
mononitrate (100 mg daily) (32). Also, during a drug-free
period to mimic times when patients might forget to take their
medications, the amlodipine plus atenolol regimen was supe-
rior at reducing ischemia, which is possibly related to the
longer acting effects of amlodipine and atenolol (Fig. 5). The
precise anti-ischemic regimen may be less important as long as
the mean heart rate is sufficiently suppressed (33,34). Reduc-
tion of silent ischemia episodes has also been documented with
aspirin, statins, and ACE inhibitors (35–37). This may be why
medical therapy appears to have such an important role in
management of silent ischemia patients.
Summary and Future Directions
Silent ischemia occurs often in patients with and without
CAD. Initial studies documented that silent ischemia pro-
vided independent prediction of adverse outcomes. ACIP,
which enrolled patients in the 1990s, found that revascular-
ization was better than medical therapy in reducing silent
ischemic episodes. Further, ACIP demonstrated a trend
toward decreased CV event rates in those patients with a
greater reduction in the number of ischemic episodes. The
more recent COURAGE and STICH trials demonstrated
Figure 5 Suppression of Ischemic Episodes With Various Medic
Ischemic episodes are reduced with various medical regimens. Typical circadian p
Adapted, with permission, from Deanfield et al. (32).similar outcomes between those patients with CAD who
preceived revascularization and optimal medical therapy com-
pared with optimal medical therapy alone. The medical ther-
apy provided in COURAGE and STICH included aspirin,
beta-blockers, statins, and ACE inhibitors, which was used at
a much greater frequency than among ACIP patients. Separate
studies have demonstrated the ability of all of these different
medical therapies to suppress silent ischemic episodes, which
may explain why medical therapy was as effective as revascu-
larization in these more recent studies.
Consideration of silent ischemia may still be important
for certain patients with CAD. The COURAGE and
STICH trials did not evaluate for evidence of silent
ischemia with AECG monitoring after treatment; there-
fore, it remains unclear if silent ischemia persists despite
current era treatment. Presence of significant silent isch-
emia in the current era of optimal medical therapy might
still identify a subset of patients with increased risk of CV
events. Thus, silence may not always be golden. Also,
silent ischemia is likely to occur with significant fre-
quency in heart transplant patients with denervated
hearts and coronary allograft vasculopathy, and future
study aimed at improving the diagnosis and treatment of
silent ischemia in this population is warranted. Addition-
ally, future research is warranted to study the effect of
newer medical therapies such as ranolazine or selected use
of revascularization (for example, guided by fractional
flow reserve) in those patients with persistent silent
ischemia despite optimal current-era medical therapy.
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